Home › Hodgkin Lymphoma › Maryland › Baltimore
Hodgkin Lymphoma clinical trials in Baltimore, MD
3 studies for Hodgkin Lymphoma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Johns Hopkins, Baltimore
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Johns Hopkins University, Baltimore
About Hodgkin Lymphoma
Hodgkin lymphoma is a type of lymphoma, cancer of the lymph system. It is serious but can usually be cured if found and treated early. Learn more.
More about Hodgkin Lymphoma on MedlinePlus
Hodgkin Lymphoma trials in other cities
- Houston, TX14 studies
- New York City, NY11 studies
- Baldwin Park, CA9 studies
- Boston, MA9 studies
- Miami, FL8 studies
- Memphis, TN7 studies
- Philadelphia, PA6 studies
- Greenburgh, NY5 studies
- Mountain View, CA5 studies
- Atlanta, GA5 studies
- Durham, NC4 studies
- Madison, WI4 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Colorectal Cancer31 studies
- Pancreatic Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.